Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb5871 (Obexelimab) in Systemic Lupus Erythematosus
NCT02725515Phase 2Completed
- Sponsor
- Xencor
- Start
- Feb 2016
- Primary completion
- Jul 2018
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obexelimab in systemic lupus erythematosus (SLE), sponsored by Xencor. Started Feb 2016; status: completed.
02
Drugs
obexelimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02725515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725515.